Stem Cell Medicine Ltd.   Report issue

For profit Phase 2
Founded: Jerusalem Israel (2010)

Organization Overview

First Clinical Trial
2019
NCT03696485
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Stem Cell Medicine Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

scm-010 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Neoplasm Metastasis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1